// Summary
This week's NIH ClinicalTrials.gov pull surfaces 10 active or newly registered studies spanning oncology, metabolic disease, autoimmune, and device/cardiology verticals. Two Phase III programs are in motion — including a new Eli Lilly combination study in obesity/T2D — alongside a first-in-human Phase I safety trial and a large NIH-sponsored Phase II autoimmune trial. No terminations or Phase III readouts (completions) were reported this cycle.
| Total | 10 |
| Phase III | 2 |
| Phase II | 1 |
| Phase I | 1 |
| NA (device/behavioral) | 4 |
| Observational (no phase) | 2 |
| Terminations flagged | 0 |
// Phase III
EloraTZP Combination in Obesity/Type 2 Diabetes
| ID | NCT07881458 |
| Status | Not yet recruiting |
| Sponsor | Eli Lilly and Company |
| Condition | Obesity, Overweight, Type 2 Diabetes |
| Intervention | Eloralintide + tirzepatide (LY900043) vs. tirzepatide |
| Primary Endpoint | Percent change from baseline in body weight (Week 100) |
| Enrollment | 1,000 (estimated) |
Lilly's amylin-agonist/tirzepatide combo heads into a large, long-duration Phase III (through 2029). Watch for enrollment initiation in November; this is a key incremental-efficacy test against tirzepatide monotherapy ahead of label expansion.
Metformin for Insulin Resistance Post-Chemotherapy
| ID | NCT06763328 |
| Status | Recruiting |
| Sponsor | City of Hope Medical Center |
| Condition | Stage I-III Breast Cancer (post-chemo insulin resistance) |
| Intervention | Extended-release metformin |
| Primary Endpoint | HbA1c normalization (up to 12 months) |
| Enrollment | 80 (estimated) |
Investigator-sponsored Phase III testing repurposed metformin for metabolic sequelae of breast cancer treatment — a niche supportive-care indication, not a registrational oncology trial.
// Phase II
Omega-3 Supplementation in Dermatomyositis
| ID | NCT07111065 |
| Status | Recruiting |
| Sponsor | National Institute of Environmental Health Sciences (NIEHS/NIH) |
| Condition | Adult and Juvenile Dermatomyositis |
| Intervention | Fish oil (O3FA) vs. placebo |
| Primary Endpoint | ACR-EULAR Myositis Response Criteria Total Improvement Score (Week 0–24) |
| Enrollment | 3,000 (estimated) |
Notably large N for a Phase II in a rare autoimmune indication — NIH-backed, double-blind design lends credibility to a nutraceutical hypothesis rarely tested at this scale.
// Phase I
OPF-110 First-in-Human Safety Study
| ID | NCT07848334 |
| Status | Active, not recruiting |
| Sponsor | Otsuka Pharmaceutical Factory, Inc. |
| Condition | Healthy Volunteers |
| Intervention | OPF-110 vs. active comparator (SMOFLIPID) |
| Primary Endpoint | Number of adverse events (Day 1–10) |
| Enrollment | 24 (estimated) |
Single ascending-dose SAD study nearing completion (Oct 2026); an early safety gate for Otsuka's undisclosed pipeline candidate.
// NA Phase (Device, Behavioral & Procedural Studies)
Supira System Pivotal in High-Risk PCI
| ID | NCT07296744 |
| Status | Recruiting |
| Sponsor | Supira Medical (Industry) |
| Condition | Coronary Artery Disease / High-Risk PCI |
| Intervention | Supira System vs. Impella |
| Primary Endpoint | Composite safety and efficacy outcome (30 days) |
| Enrollment | 358 (estimated) |
A direct head-to-head pivotal against Abiomed's Impella — the mechanical circulatory support space's most closely watched device competition this cycle.
Phasix Mesh for Incisional Hernia Prevention
| ID | NCT03911700 |
| Status | Active, not recruiting |
| Sponsor | C. R. Bard (Industry) |
| Condition | Open Midline Laparotomy |
| Intervention | Phasix Mesh (bioabsorbable) |
| Primary Endpoint | Rate of incisional hernia (24 months) |
| Enrollment | 477 (actual) |
Long-running Bard device trial now tracking toward a 2031 completion; durability data at 24 months will be the key commercial catalyst.
GAIN-S: Telemedicine for Geriatric Oncology Care
| ID | NCT06022965 |
| Status | Recruiting |
| Sponsor | City of Hope Medical Center |
| Condition | Hematologic and Solid Malignancies (older adults) |
| Intervention | Telemedicine-delivered geriatric assessment + supportive care |
| Primary Endpoint | Advance directive completion rate (baseline, 3 months) |
| Enrollment | 216 (estimated) |
Avocado Consumption for Sleep/Skin Health
| ID | NCT07880444 |
| Status | Not yet recruiting |
| Sponsor | San Diego State University |
| Condition | Poor Sleep Quality (postmenopausal women) |
| Intervention | Hass avocado vs. safflower oil |
| Primary Endpoint | Change in actigraphy-derived sleep efficiency (Weeks 0/4/8) |
| Enrollment | 74 (estimated) |
// Observational Studies (No Phase)
Difficult Tracheal Intubation Risk Factors
| ID | NCT07881107 |
| Status | Completed |
| Sponsor | Bursa City Hospital (Turkey) |
| Condition | Difficult Tracheal Intubation/Laryngoscopy/Mask Ventilation |
| Primary Endpoint | Difficult tracheal intubation incidence (day of surgery) |
| Enrollment | 812 (actual) |
Post-Intensive Care Syndrome in COVID Survivors
| ID | NCT03738774 |
| Status | Active, not recruiting |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Post-Intensive Care Syndrome |
| Primary Endpoint | Deaths or hospital readmissions within 3 months of discharge |
| Enrollment | 200 (estimated) |
